

Use your outcomes data to achieve product development and market access objectives.

Putting Data to Work for You

Make the most of your outcomes research data. Our team of scientists will work with you to deliver rapid and precise results for your regulatory submissions, value dossiers, and publications.

We understand both the rigor needed for clinical studies and the challenges of analyzing outcomes data. Our statisticians work in a fully compliant regulated environment using a validated SAS server.

Turn to us for expertise in the research areas below:

Quality of Life

- Experience with scoring and analyzing multiple instruments
- Application of longitudinal and missing data models including repeated measures and pattern-mixture models
- Responder and cumulative density function analyses

Health Care Resource Utilization

- Application of unit costs to trial endpoints
- Analysis of non-normal cost data

Meta-Analyses

- Direct and indirect comparisons
- Network analyses with mixed-treatment comparisons (MTC)

Exploratory Analyses

- Extrapolation of survival endpoints for cost-effectiveness models
- Evaluation of relationships among endpoints



Contact Us:
info@rtihs.org
www.rtihs.org

Key Technical Staff

Beth Sherrill, MS

Vice President, Biostatistics
bsherrill@rti.org

Dawn Odom, MS

Global Head, Biostatistics
dodom@rti.org

Jianmin Wang, PhD, MD

Director, Biostatistics, US
jwang@rti.org

Selected Publications

Blum JL, Kohles J, McKenna E, Scotto N, Hu S, **Odom D**, et al. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. *Breast Cancer Res Treat.* 2011;125(2):431-9.

Chung RT, Poordad FF, Hassanein T, **Zhou X**, Lentz E, Prabhakar A, Di Bisceglie AM. Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. *Hepatology.* 2010;52(6):1906-14.

Kaufman B, Wu Y, Amonkar MM, **Sherrill B**, Bachelot T, Salazar V, et al. Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancer. *Curr Med Res Opin.* 2010 May;26(5):1065-73.

Mangel AW, Bornstein JD, **Hamm LR**, Buda J, **Wang J**, Irish W, Urso D. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. *Aliment Pharmacol Ther.* 2008 Jul;28(2):239-49.

Odom D, Barber B, **Bennett L**, Peeters M, Zhao Z, **Kaye J**, et al. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. *Int J Colorectal Dis.* 2011 February; 26(2): 173–181.

Oglesby A, Sherif B, **Odom D**, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. *Community Oncol.* 2009;6: 494-502.

Pendergast K, Wolf A, **Sherrill B**, **Zhou X**, Aronne LJ, Caterson I, et al. Impact of waist circumference difference on health-care cost among overweight and obese subjects: the PROCEED cohort. *Value Health.* 2010 Jun-Jul;13(4):402-10.

Pockros PJ, Hamzeh FM, Martin P, Lentz E, **Zhou X**, Govindarajan S, Lok AS. Histologic outcomes in hepatitis C-Infected patients with varying degrees of virologic response to interferon-based treatments. *Hepatology.* 2010;52(4):1193-200.

Reau N, Hamzeh FM, Lentz E, **Zhou X**, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. *J Viral Hepat.* 2011 Feb 1;19(2):94-102.

Sherrill B, Amonkar MM, Sherif B, Maltzman J, O'Rourke L, Johnston S. Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. *Oncologist.* 2010;15(9):944-53.

Sherrill B, Di LA, Amonkar MM, Wu Y, Zvirbule Z, Aziz Z, et al. Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. *Curr Med Res Opin.* 2010 Apr 1;26(4):767-75.

Wang J, **Sherrill B**, **Hamm LA**, **Mangel AW**. Does timing of colon procedures affect outcomes in D-IBS trials? *Gastroenterol Res.* 2010;3(5):185-90.

Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. *Thromb Haemost.* 2010 Feb;103(2):360-71.

Zhou X, Cella D, Cameron D, Amonkar MM, Segreti A, Stein S, et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. *Breast Cancer Res Treat.* 2009;117(3):577-89.